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ABSTRACT 
Even though an agreed phenotypic definition of circulating tumor cells (CTCs) remains elusive in the literature, 
many current detection technologies isolate candidate cells based on molecular recognition of cellular epitopes that 
may not accurately predict CTC load. Rather than using such an epitope specific “positive-capture” strategy, we 
present a chip-based, centrifugal microfluidic platform integrating “negative-capture” magnetophoretic removal of 
normal white blood cells (WBCs) from a sample and subsequent, array-based enumeration of individualized, 
(untagged) abnormal cells. We compared the numerical recovery of cells on the array with the status of the donor 
patient, showing that the chip can has the potential to indicate the oncogenic severity of the blood donor. 
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INTRODUCTION 
With advances in modern therapies, the prognosis for patients presenting with cancer can be positive in cases 
where malignancies are detected early. The detection and / or enumeration of CTCs in patient blood is one of the 
most promising, minimally invasive diagnostic methods to have emerged from translational medicine in recent years 
[1]. Isolation of CTCs from a sample is generally mediated through antibody binding to a target outer-membrane 
epitope and subsequent removal of bound cells from the sample or immobilization of cells to a solid phase; 
alternatively, separation of CTC candidates by size exclusion has been implemented. However, such methods are 
limited by the inherent heterogeneity within CTC populations. For example, the most common epitope targeted is 
EpCAM, an exclusively epithelial marker. Detection of EpCAM expressing cells in blood is often used as part of a 
positive signature for a CTC. Yet, some CTCs do not express EpCAM or other common markers such as 
cytokeratin. Indeed, EpCAM is down-regulated during epithelial-to-mesenchymal transition (EMT); also in many 
carcinomas EpCAM is under-expressed or not expressed at all [2]. 
In the current work, we present a strategy to overcome the inherent heterogeneity of CTCs by using a negative 
isolation mode rather than the epitope specific positive isolation described above. In this mode, instead of targeting 
CTCs directly, normal WBCs are bound to paramagnetic beads and isolated to a magnetic locus upstream of a 
cellular detection array in a centrifugal chip. Hence, as the cells naturally found in blood are excluded, only 
abnormal cells that escape binding will resolve to the detection array. The higher the number of cellular events 
recorded at the detection array will then provide an indication as to the extent of CTC load within a blood sample. 
There is a minor loss of candidate cells which become entrained in the collective migration of abundant tagged cells 
towards the lateral magnets; however, a sufficient number of candidate cells resolves to the detection array to 




Figure 1: Schematic of the negative isolation blood analysis chip featuring the chambers for loading, magnetic 
separation and detection in a V-cup array. The separation chamber (red hatched box) is shown in more detail, and 
demonstrates the sequestering of cells expressing CD15 and CD45 from the sample. Un-deflected cells migrate into 
the V-cups under the influence of the radial force. 
THEORY 
Our group has previously shown the use of centrifugo-magnetophoresis as an efficient method for isolating cells 
of interest from a blood sample [3, 4]. In the here presented system, centrifugo-magnetophoresis is used to 
immobilize healthy WBCs within the fluidic chamber of the centrifugal chip after incubation of processed blood 
sample with paramagnetic beads targeting both CD15 and CD45. These markers are absent in abnormal cells which 
are thus driven by the radial, centrifugal force to the outer region of the chip where an array of scale-matched traps 
aligns them in a regular grid featuring single-occupancy distribution (Fig. 1). The array consists of 7410 individual 
posts, each shaped such that only a single cell can occupy the cup-like indentation at the top (Fig. 1). As the 
specificity is based on removal of phenotypically well-defined healthy WBCs, our system circumvents the issue of 
CTC heterogeneity, regardless of epitope expression or cell size. As negative selection is used, no further 
characterization of the cells occupying the cups is required (i.e. fluorescent measurements were not used) to identify 
the cells as candidate CTCs. Hence, the occupancy of the array is measured simply by optically scoring each cup as 
occupied or non-occupied. 
 
EXPERIMENTAL 
Whole blood was isolated from either healthy volunteers or patients harboring primary (ovarian and melanoma) 
or recurrent (ovarian) tumors. Where indicated, whole blood was spiked with LnCAP cells pre-stained with Hoechst 
33342 to simulate abnormal cells. RBCs were removed using hypotonic lysis, and the remaining nucleated cells 
isolated by centrifugation, re-suspended  in 500 µl of resuspension buffer, and enumerated. paramagnetic beads 
functionalized against CD15 and CD45 (Life Technologies) were added to the samples and rotated for 20 minutes at 
4°C. Chips were then loaded with a volume of sample representing the nucleated cell load equivalent to 2.5 µl of 
original whole blood, and rotated at 10 Hz for 45 minutes. The V-cup array was visualized using optical brightfield 
(or fluorescent where indicated) microscopy to quantitate the occupancy of the array.  
 
RESULTS AND DISCUSSION 
To demonstrate the operation and efficiency of the negative-isolation and cellular distribution chip, Fig. 2 shows the 
results of an experiment where 50 cultured LnCAP cells stained with Hoechst 33342 were spiked to a healthy blood 
sample and processed through the chip as described. In this experiment, a total of 33 cells were retrieved on the V-cup 
array; composed of all 30 LnCAP cells (as identified by their specific stain) and a remainder of only 3 being (normal) 
WBCs, despite their huge abundance in the original sample. These data demonstrate a 90% specificity and a 60% 
sensitivity for the detection of abnormal cells. 
 
 
Figure 2: Identification of LnCAP cancer cells spiked to a healthy blood sample using the blood analysis chip. The full 
V-cup array is shown with locations of LnCAP cells (blue) and normal WBCs (red) marked for clarity. Inserts are 
zoomed images of LnCAP and normal cells in V-cups. 
 
Blood samples from melanoma and ovarian cancer patients with either primary or recurrent tumors were processed 
identically (without cellular spikes) and compared to a healthy blood sample by brightfield observation of the 
occupancy of the V-cup array (Fig. 3). As expected, blood from the healthy volunteer resolved no cellular events to the 
V-cups following processing  while the all samples from cancer patients exhibited events on the array (Fig. 3i). 
Furthermore, the number of events was markedly higher (Fig. 3ii) in the sample from the patient with recurrent tumors 




Figure 3: (i) Abnormal cell identification in patient-sourced blood samples. Samples from healthy patients did not 
display any detectable cells in V-cups, but patients with primary cancer and recurrent tumor harbored cells that 
populated the capture array. Furthermore, patients with recurrent tumor showed a higher level of capture. (ii) 
Analysis of cell count read on the V-cup array relative to the status of the blood donor. 
 
CONCLUSION 
We introduced a stopped-flow, centrifugo-magnetophoretic strategy to identify and enumerate CTC candidates 
from a blood sample in an array with single-occupancy distribution by conventional, brightfield microscopy. We 
demonstrated that our technique can identify samples from healthy patients and even distinguish between samples 
from patients with varying severity of cancer. Although the sensitivity is currently limited due to capture of a sub-
population of target cells at the magnetic array, the specificity is high. Our negative-selection method avoids a po-
tential bias that arises from other, positive-selection methods that use epitope- or size-based targeting of candidate 
cells. The strategy is thus applicable to all cancer types studied via blood sampling, including the detection of cells 
that do not express the well-known epitopes such as EpCAM or cytokeratin, or that display a size range that over-
laps with normal white blood cells. 
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